Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients - A large European trial

American Journal of Transplantation

Volumn 6, Issue 6, 2006, Pages 1387-1397

  Grimm, M ^a   Rinaldi, M ^b   Yonan, N A ^c   Arpesella, G ^d   Arizon Del Prado J M ^e   Pulpon L A ^f   Villemot, J P ^g   Frigerio, M ^h   Rodriguez Lambert, J L ⁱ   Crespo Leiro, M G ^j   Almenar, L ^k   Duveau, D ^l   Ordonez Fernandez, A ^m   Gandjbakhch, J ⁿ   Maccherini, M ^o   Laufer, G ^p  

^a UNIVERSITY OF VIENNA   (Austria)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c WYTHENSHAWE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^f HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^g CHU NANCY BRABOIS   (France)

^h OSPEDALE NIGUARDA CA GRANDA   (Italy)

ⁱ HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^j HOSPITAL JUAN CANALEJO   (Spain)

^k HOSPITAL UNIVERSITARIO LA FE   (Spain)

^l CHU de Nantes   (France)

^m HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

ⁿ PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^o UNIVERSITY HOSPITAL OF SIENA   (Italy)

^p UNIVERSITY OF INNSBRUCK   (Austria)

more..

Author keywords

Acute rejection; Cyclosporine; Heart transplantation; Hyperlipidemia; Hypertension; Tacrolimus

Indexed keywords

ANTILIPEMIC AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; INSULIN; OKT 3; ORTHOCLONE; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ACUTE KIDNEY FAILURE; ADULT; ANEMIA; ARTICLE; ASPERGILLUS; BIOPSY; CARDIAC GRAFT REJECTION; CHOLELITHIASIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DISORDERS OF CARBOHYDRATE METABOLISM; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DYSLIPIDEMIA; FEMALE; GINGIVA HYPERPLASIA; GRAFT SURVIVAL; HERPES SIMPLEX; HERPES ZOSTER; HIRSUTISM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION; KAPOSI SARCOMA; KIDNEY CARCINOMA; KIDNEY DISEASE; KIDNEY DYSFUNCTION; LEGIONELLA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MICROEMULSION; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; SEPSIS; SKIN CARCINOMA; SURVIVAL; TESTIS CANCER; THRUSH; TOXOPLASMOSIS; TREMOR; URINARY TRACT INFECTION;

EID: 33745833087     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2006.01300.x     Document Type: Article

References (34)

1. Marcus N, Khaghani A, Burke M, Yacoub M, Banner N. Medium-term outcome of tacrolimus immunosuppression following rejection or graft dysfunction in heart transplant patients. Transplant Proc 1998; 30: 1134-1135.
2. Mentzer RM Jr, Jahania MS, Lasley RD and the US Multicenter FK506 Study Group. Tacrolimus as a rescue immunosuppressant after heart and lung transplantation. Transplantation 1998; 65: 109-113.
3. Taylor DO, Edwards LB, Boucek MM, Trulock EP, Keck BM, Hertz MI. The Registry of the International Society for Heart and Lung Transplantation: Twenty-first Official Adult Heart Transplant Report-2005. J Heart Lung Transplant 2004; 24: 945-955.
4. Meiser BM, Schmidt D, Pfeiffer M et al. Comparison of long-term effects between tacrolimus and cyclosporine based immunosuppression after HTx (Abstract 179). J Heart Lung Transplant 1999; 18: 78.
5. Rinaldi M, Pellegrini C, Martinelli L et al. FK506 effectiveness in reducing acute rejection after heart transplantation: A prospective randomized study. J Heart Lung Transplant 1997; 16: 1001-1010.
6. Pham SM, Kormos RL, Hattler BG et al. A prospective trial of tacrolimus (FK506) in clinical heart transplantation: Intermediate-term results. J Thorac Cardiovasc Surg 1996; 111: 764-772.
7. Taylor DO, Barr ML, Radovancevic B et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: Decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant 1999; 18: 336-345.
8. Reichart B, Meiser B, Vigano M et al. European multicenter tacrolimus (FK506) heart pilot study: One-year results - European tacrolimus multicenter heart study group. J Heart Lung Transplant 1998; 17: 775-781.
9. Madden BP for the European Tacrolimus Heart Study Group. Results of tacrolimus in cardiac transplanation following intravenous tacrolimus administration. J Heart Lung Transplant 2000; 19: 102.
10. Podesser BK, Rinaldi M, Yonan N et al. Comparison of low and high initial tacrolimus dosing in primary heart transplant recipients: a prospective European multicenter study. Transplantation 2005; 79: 65-71.
11. Billingham ME. Dilemma of variety of histopathologic grading systems for acute cardiac allograft rejection by endomyocardial biopsy. J Heart Transplant 1990; 9: 272-276.
12. American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003; 26(Suppl1): S5.
13. Russell SD. An update on the efficacy of newer immunosuppressive regimens in cardiac transplantation. Curr Opin Organ Transplant 2004; 9: 453-457.
14. Kobashigawa J, Miller L, Renlund D et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation 1998; 66: 507-515.
15. Koegh A, Richardson M, Ruygrok P et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: A randomized clinical trial. Circulation 2004; 110: r10-r16.
16. Eisen HJ, Tuzcu EM, Dorent D et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847-858.
17. Kobashigawa JA, Miller LW, Russell SD et al. Tacrolimus with myocophenolate mofetil (MMF) or sirolimus versus cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 2006, in press.
18. Meiser BM, Groetzner J, Kaczmarek I et al. Tacrolimus or cyclosporine: Which is the better partner for mycophenolate mofetil in heart transplant recipients? Transplantation 2004; 78: 591-598.
19. Mehra MR, Uber PA, Scott RL, Park MH. Ethnic disparity in clinical outcome after heart transplantation is abrogated using tacrolimus and mycophenolate mofetil-based immunosuppression. Transplantation 2002; 74: 1568-1573.
20. Kirklin JK. Is biopsy-proven cellular rejection an important clinical consideration in heart transplantation? Curr Opin Cardiol 2005; 20: 127-131.
21. Marboe CC, Lal PG, Chu K et al. Nodular endocardial infiltrates (quilty lesions) cause significant variability in diagnosis of ISHLT grade 2 and 3A rejection in cardiac allograft recipients. J Heart Lung Transplant 2005; 24(7 Suppl): S219-S226.
22. Klingenberg R, Koch A, Schnabel PA et al. Allograft rejection of ISHLT grade ≥3A occurring late after heart transplantation - A distinct entity? J Heart Lung Transplant 2003; 22: 1005-1013.
23. Yamani MH, Yousufuddin M, Starling RC et al. Does acute cellular rejection correlate with cardiac allograft vasculopathy? J Heart Lung Transplant 2004; 23: 272-276.
24. Radovancevic B, Konuralp C, Vrtovec B et al. Factors predicting 10-year survival after heart transplantation. J Heart Lung Transplant 2005; 24: 156-159.
25. Chin C, Naftel DC, Singh TP et al. Risk factors for recurrent rejection in pediatric heart transplantation: A multicenter experience. J Heart Lung Transplant 2004; 23: 178-185.
26. Margreiter R for the European Tacrolimus vs Ciclosporin Microemulsion Renal Transplantation Study Group. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: A randomized multicentre study. Lancet 2002; 359: 741-746.
27. O'Grady J, Burroughs A, Hardy P et al. Tacrolimus versus microemulsified ciclosporin in liver transplantation: The TMC randomized controlled trial. Lancet 2002; 360: 1119-1125.
28. Marchetti P. New-onset diabetes after transplantation. J Heart Lung Transplant 2004; 23: 194-201.
29. Boillot O, Mayer DA, Boudjema K et al. Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: A large randomized clinical study. Liver Transpl 2005; 11: 61-67.
30. Rostaing L, Cantarovich D, Mourad G et al. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil and daclizumab induction in renal transplantation. Transplantation 2005; 79: 807-814.
31. Baran DA, Ashkar J, Galin ID et al. Tacrolimus and new onset diabetes mellitus: The effect of steroid weaning. Transplant Proc 2002; 34: 1711-1712.
32. Yamani MH, Cook DJ, Thomas D et al. The impact of antithymocyte globulin (ATG) on clinical outcome following heart transplantation: A holiday from steroids. The 3rd International Congress of Immunosuppression, 8th-11 th December, 2004, San Diego, USA (2004), p. 51, Abstr. 18.
33. Mühlbacher F for the European Liver Transplantation Tacrolimus vs Cyclosporine Microemulsion Study Group. Tacrolimus versus cyclosporin microemulsion in liver transplantation: Results of a 3-month study. Transplant Proc 2001; 33: 1339-1340.
34. Claesson K, Mayer AD, Squifflet JP et al. Lipoprotein patterns in renal transplant patients: A comparison between FK506 and cyclosporine A patients. Transplant Proc 1998; 30: 1292-1294.